Related Experiment Video

Updated: Aug 8, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Are generic formulations of carvedilol of inferior pharmaceutical quality compared with the branded formulation?

Julian C Smith1, Giorgio Tarocco, Fabio Merazzi

  • 1Pharmaceutical Sciences, Aston University, Birmingham, UK. j.c.smith@aston.ac.uk

Current Medical Research and Opinion
|May 11, 2006
PubMed

Insights

Many generic carvedilol products fail quality tests, raising concerns about treatment efficacy and safety. Pharmaceutical quality assessments revealed significant issues with tablet hardness and dissolution in generic carvedilol formulations.

Area of Science:

  • Pharmaceutical Sciences
  • Drug Quality Assessment
  • Pharmacology

Background:

  • Carvedilol is a crucial beta-blocker for hypertension, angina, and heart failure.
  • Marketed as Dilatrend and Coreg, it addresses various cardiovascular conditions.

Purpose of the Study:

  • To evaluate the pharmaceutical quality of generic carvedilol products.
  • To compare generic formulations against the original Dilatrend and pharmacopoeial standards.

Main Methods:

  • Assessed carvedilol content, tablet hardness, dissolution, and purity.
  • Tested Dilatrend tablets and 35 generic carvedilol products from 20 manufacturers.

Main Results:

  • All Dilatrend strengths met specifications.
  • 48.6% of generic carvedilol products failed quality specifications.
  • Common failures included incorrect hardness (11 products) and inadequate dissolution (9 products).
  • Seven generic products failed multiple quality tests.

Conclusions:

  • Significant variability exists in generic carvedilol quality.
  • Substandard generic carvedilol may impact patient treatment efficacy and safety.
  • Pharmaceutical quality is critical for ensuring bioequivalence and therapeutic outcomes.
Abstract

Related Concept Videos

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...